MAP2K7 and breast carcinoma: The lack of frequent mutations within the core Ras-Raf-MEK axis, but the potential for cross-talk with a plethora of pathways intrinsic to breast cancer progression, may mean that the potential of MEK blockade lies in treatment combinations to overcome resistance.